[go: up one dir, main page]

NO20063196L - Nye fusjonerte pyrrolokarbazoler - Google Patents

Nye fusjonerte pyrrolokarbazoler

Info

Publication number
NO20063196L
NO20063196L NO20063196A NO20063196A NO20063196L NO 20063196 L NO20063196 L NO 20063196L NO 20063196 A NO20063196 A NO 20063196A NO 20063196 A NO20063196 A NO 20063196A NO 20063196 L NO20063196 L NO 20063196L
Authority
NO
Norway
Prior art keywords
fused pyrrolocarbazoles
new fused
pyrrolocarbazoles
present
new
Prior art date
Application number
NO20063196A
Other languages
English (en)
Other versions
NO336893B1 (no
Inventor
Robert L Hudkins
Diane E Gingrich
Dandu R Reddy
Ming Tao
Theodore L Underiner
Allison L Zulli
Nadine C Becknell
James L Diebold
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20063196L publication Critical patent/NO20063196L/no
Publication of NO336893B1 publication Critical patent/NO336893B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)

Abstract

Foreliggende oppfinnelse angår generelt utvalgte kondenserte pyrrolokarbazoler, omfattende farmasøytiske preparater derav og metoder for behandling av sykdommer med dem. Foreliggende oppfinnelse angår også mellomprodukter og prosesser for fremstilling av disse kondenserte pyrrolokarbazoler.
NO20063196A 2003-12-23 2006-07-10 Nye fusjonerte pyrrolokarbazoler, deres anvendelse, samt farmasøytisk preparat omfattende de samme NO336893B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53218203P 2003-12-23 2003-12-23
US11/017,947 US7169802B2 (en) 2003-12-23 2004-12-22 Fused pyrrolocarbazoles
PCT/US2004/043160 WO2005063763A1 (en) 2003-12-23 2004-12-23 Novel fused pyrrolocarbazoles

Publications (2)

Publication Number Publication Date
NO20063196L true NO20063196L (no) 2006-09-20
NO336893B1 NO336893B1 (no) 2015-11-23

Family

ID=34703676

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20063196A NO336893B1 (no) 2003-12-23 2006-07-10 Nye fusjonerte pyrrolokarbazoler, deres anvendelse, samt farmasøytisk preparat omfattende de samme
NO20151245A NO20151245A1 (no) 2003-12-23 2015-09-23 Nye kondenserte pyrrolokarbazolforbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20151245A NO20151245A1 (no) 2003-12-23 2015-09-23 Nye kondenserte pyrrolokarbazolforbindelser

Country Status (29)

Country Link
US (4) US7169802B2 (no)
EP (1) EP1704148B1 (no)
JP (1) JP5006046B2 (no)
KR (2) KR101179372B1 (no)
CN (1) CN1918162B (no)
AR (1) AR047168A1 (no)
AT (1) ATE500256T1 (no)
AU (1) AU2004309394B2 (no)
BR (1) BRPI0418113B8 (no)
CA (1) CA2549627C (no)
CR (1) CR8519A (no)
CY (1) CY1111524T1 (no)
DE (1) DE602004031672D1 (no)
DK (1) DK1704148T3 (no)
EA (1) EA012295B1 (no)
HR (1) HRP20110373T1 (no)
IL (1) IL176384A (no)
IS (1) IS8519A (no)
MA (1) MA28298A1 (no)
MY (2) MY143373A (no)
NO (2) NO336893B1 (no)
NZ (1) NZ548099A (no)
PL (1) PL1704148T3 (no)
PT (1) PT1704148E (no)
RS (1) RS51886B (no)
SG (1) SG149045A1 (no)
SI (1) SI1704148T1 (no)
TW (1) TWI355385B (no)
WO (1) WO2005063763A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20090270511A1 (en) * 2006-09-08 2009-10-29 Merck Frosst Canada Ltd. Prodrugs of inhibitors of cathepsin s
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
EP2167075A4 (en) * 2007-06-08 2012-07-11 Univ Massachusetts MIXED LINEAGE KINASES AND METABOLISM DISORDER
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
CA2741089A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
AU2009316600B2 (en) * 2008-11-19 2015-09-24 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2192121A1 (en) 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
WO2010078427A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
RU2012120783A (ru) * 2009-10-22 2013-11-27 Женентек, Инк. Модуляция дегенерации аксона
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
MY156830A (en) 2010-05-18 2016-03-31 Cephalon Inc Method for purifying a fused pyrrolocarbazole derivative
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
US10386370B2 (en) 2013-02-11 2019-08-20 Incuron, Inc. Use of facilitates chromatin transcription complex (FACT) in cancer
US9884853B2 (en) * 2013-09-26 2018-02-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3129022A4 (en) 2014-04-06 2018-02-21 Incuron, Llc Combination therapies with curaxins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
AU710669B2 (en) 1996-08-22 1999-09-23 Bristol-Myers Squibb Company Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
AU2001292579A1 (en) 2000-09-29 2002-04-15 Eli Lilly And Company Methods and compounds for treating proliferative diseases
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
IL176384A0 (en) 2006-10-05
HK1096096A1 (en) 2007-05-25
MY143373A (en) 2011-04-29
US20100152196A1 (en) 2010-06-17
WO2005063763A1 (en) 2005-07-14
AU2004309394A1 (en) 2005-07-14
NO20151245A1 (no) 2015-09-23
CA2549627A1 (en) 2005-07-14
KR20120066057A (ko) 2012-06-21
MA28298A1 (fr) 2006-11-01
JP2007516293A (ja) 2007-06-21
DK1704148T3 (da) 2011-06-14
US20120004253A1 (en) 2012-01-05
SI1704148T1 (sl) 2011-06-30
KR101179372B1 (ko) 2012-09-03
PL1704148T3 (pl) 2011-07-29
RS51886B (sr) 2012-02-29
CA2549627C (en) 2012-12-11
JP5006046B2 (ja) 2012-08-22
PT1704148E (pt) 2011-05-25
IS8519A (is) 2006-06-22
CN1918162B (zh) 2014-05-14
EA200601217A1 (ru) 2006-12-29
CN1918162A (zh) 2007-02-21
US7671064B2 (en) 2010-03-02
CR8519A (es) 2007-06-06
DE602004031672D1 (de) 2011-04-14
TWI355385B (en) 2012-01-01
US7169802B2 (en) 2007-01-30
EP1704148B1 (en) 2011-03-02
MY158159A (en) 2016-09-15
BRPI0418113B1 (pt) 2020-04-14
SG149045A1 (en) 2009-01-29
BRPI0418113A (pt) 2007-04-17
ATE500256T1 (de) 2011-03-15
BRPI0418113B8 (pt) 2021-05-25
EP1704148A1 (en) 2006-09-27
US8044064B2 (en) 2011-10-25
US8383813B2 (en) 2013-02-26
IL176384A (en) 2015-05-31
US20060247294A1 (en) 2006-11-02
AR047168A1 (es) 2006-01-11
HRP20110373T1 (hr) 2011-06-30
NZ548099A (en) 2010-05-28
AU2004309394B2 (en) 2011-04-28
EA012295B1 (ru) 2009-08-28
US20050143442A1 (en) 2005-06-30
TW200530243A (en) 2005-09-16
KR20060127069A (ko) 2006-12-11
CY1111524T1 (el) 2015-08-05
NO336893B1 (no) 2015-11-23

Similar Documents

Publication Publication Date Title
NO20063196L (no) Nye fusjonerte pyrrolokarbazoler
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
NO20060230L (no) Nye aminobenzofenonforbindelser
TW200740844A (en) Novel MAdCAM antibodies
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
SE0301010D0 (sv) Novel compounds
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
SE0301009D0 (sv) Novel compounds
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
NO20052928L (no) Nye kjemiske forbindelser
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
NO20050091L (no) Fremgangsmater for fremstilling av fibrinogen
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
NO20055741D0 (no) Nye kjemiske forbindelser
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
IL182340A0 (en) Method for the isolation of haptoglobin
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
UA87829C2 (en) Fused pyrrolocarbazoles
ATE410415T1 (de) Neue verbindungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees